BACKGROUND: To confirm the hypothesis that reducing the interval between surgery and adjuvant chemotherapy could improve prognosis, a randomized multicentric study of adjuvant perioperative chemotherapy (POC) in @entity0 was initiated. METHODS: A total of 552 @entity1 were randomized to evaluate whether the addition of POC to standard adjuvant treatment significantly improved outcome. @entity1 were stratified according to menopausal status, with 362 @entity1 in the postmenopausal group and 192 @entity1 in the premenopausal group. Premenopausal @entity1 with positive axillary nodes, negative hormonal receptors, or grade 3 @entity5 received adjuvant @entity2664 -based chemotherapy. Node-negative premenopausal @entity1 with grade 1 or 2 @entity5 expressing hormonal receptors received no standard adjuvant treatment. All postmenopausal @entity1 received hormonal therapy ( @entity440 20 mg/day for 3 years). The perioperative regimen was a 14 mg/m(2) @entity2664 infusion at the end of @entity5 excision. RESULTS: With a median follow-up of 6.1 years, this study showed no significant advantage of POC on overall survival, disease-free survival, or @entity3 -free survival for the total cohort or for the premenopausal and postmenopausal groups. CONCLUSIONS: POC was a safe procedure in this study. However, the addition of POC to standard adjuvant treatment offered no benefit in @entity0 adjuvant treatment.

Randomized multicentric study of perioperative chemotherapy with XXXX in early @entity0 .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity2664 :: (MESH:D008942,Chemical) :: ['mitoxantrone']
